Preparation and application of nitrogen-based photo-crosslinking magnetic carbon biological probe
By fixing CD-ATFB-FK506 on the surface of Fe3O4@C nanoparticles, a nitrogen-type photocrosslinked magnetic carbon biological probe was formed, which solved the problems of non-specific adsorption and small molecule derivatization in affinity chromatography, and achieved the target protein Efficient capture and release, simplifying probe synthesis, suitable for drug target detection.
Patent Information
- Application Number
- CN202411030650.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing affinity chromatography has problems with nonspecific adsorption proteins and difficulties in target recognition, resulting in signal masking of target proteins and false positive results. The research on structural activity relationships is time-consuming and labor-intensive, limiting the probe. synthesis progress.
Using the preparation method of nitrogen-bin type photocrosslinked magnetic carbon biological probe, CD-ATFB-FK506 is fixed on the surface of Fe3O4@C nanoparticles by amide condensation, forming Fe3O4@C-CD-ATFB-FK506 probe, using ultraviolet light The cross-linking method quickly fixes small molecules, simplifying the probe synthesis process.
It improves the affinity purification efficiency, reduces non-specific adsorption, simplifies the probe synthesis process, reduces costs, and achieves efficient capture and release of target proteins, which is suitable for drug target detection.
Smart Images

Figure CN118949927A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to the preparation and application of a nitrene-type photo-crosslinked magnetic carbon biological probe. Background Art
[0002] Confirming drug targets is a prerequisite for drug discovery and screening, including target identification and verification. Drugs can bind to corresponding targets in organisms and show drug responsiveness as receptor agonists or inhibitors, and are used in disease treatment. In recent years, with the development of pharmacology, the cognition of "one disease, one drug, one gene, one target" has gradually been replaced by "polypharmacology", that is, a multifunctional drug can target multiple proteins at the same time. Among hundreds of thousands of different proteins, there are about 3,000-10,000 available drug targets, but only about 500 targets have been developed for targeted therapy. Target identification is not only meaningful for clarifying the biological mechanism of action of compounds, but also can be used to identify certain proteins related to so-called "non-targets" or adverse side effects of known therapeutic drugs, that is, additional target proteins may cause adverse biological effects and toxicity. Therefore, it is necessary to develop a more accurate and effective method to explore the mechanism of action of drugs to exert pharmacological activity, accurately discover and effectively verify targets, which is of great significance to drug research and development.
[0003] The capture of targets in direct target recognition strategies can be achieved through effective non-covalent interactions (affinity-based proteomics) or covalent interactions (activity-based proteomics). In affinity-based proteomics, affinity chromatography (affinity purification) is the most widely used method. It can use the affinity between bioactive small molecules and target proteins to separate and identify target proteins of specific ligands. Although affinity chromatography has successfully separated and identified the target proteins of many bioactive compounds, there are still some problems with this technology that limit its application. The first problem is non-specific adsorption of proteins, which often mask the true target protein signals, resulting in false positive results and increasing the difficulty of protein spectrum analysis. Another problem is the derivatization of bioactive small molecules. Designing a probe often requires first conducting structure-activity relationship (SAR) studies on the bioactive small molecules of interest. After determining the active site of the small molecule, it is connected to the matrix without destroying its original activity. However, the application of some small molecules that do not have suitable modification sites is limited. At the same time, SAR research is time-consuming and labor-intensive, which also slows down the synthesis progress of the probe. To solve these problems, optimizing the probe structure becomes the key. As the core component in affinity chromatography, the design of the probe is crucial to improving the efficiency of affinity purification and reducing nonspecific adsorption. Summary of the invention
[0004] In order to solve the technical problems existing in the prior art, the present invention provides the following technical solutions:
[0005] The present invention provides a method for preparing a nitrene-type photo-crosslinked magnetic carbon biological probe, the preparation method comprising the following steps:
[0006] CD-ATFB-FK506 was introduced onto the Fe3O4@C surface by amide condensation to obtain the nitrene-type photo-cross-linked magnetic carbon bioprobe Fe3O4@C-CD-ATFB-FK506.
[0007] Furthermore, the preparation method comprises the following steps:
[0008] The Fe3O4@C nanoparticles were washed with methanol three times, and the photo-crosslinked composite CD-ATFB-FK506 was added, and then EDC and triethylamine were added to react. After the reaction was completed, the nanoparticles were washed to obtain Fe3O4@C-CD-ATFB-FK506.
[0009] Furthermore, the washing is methanol washing.
[0010] Furthermore, the washing is followed by quantification in water.
[0011] Furthermore, the ratio of the Fe3O4@C nanoparticles, the photo-crosslinked composite CD-ATFB-FK506, EDC, and triethylamine is 100 mg: 50 mg: 400 mg: 0.3 mL.
[0012] Furthermore, the Fe3O4@C-CD-ATFB-FK506 was stored at 4°C in the dark.
[0013] Furthermore, the reaction time is 12 hours.
[0014] In some embodiments, the method for preparing the nitrene-type photo-cross-linked magnetic carbon bioprobe fixes CD-ATFB-FK506 on the surface of magnetic carbon nanoparticles by amide condensation to prepare the FK506-fixed nitrene-type photo-cross-linked magnetic carbon bioprobe Fe3O4@C-CD-ATFB-FK506.
[0015] In some embodiments, the method for preparing the nitrene-type photocrosslinked magnetic carbon bioprobe comprises the following steps: 100 mg of Fe3O4@C nanoparticles are taken, washed three times with methanol, and CD-ATFB-FK506 photocrosslinked complex (50 mg) is prepared and added thereto. Then 400 mg of EDC and 300 μL of triethylamine are added and reacted for 12 hours. After the reaction, the material is washed several times with methanol and quantified in deionized water to obtain Fe3O4@C-CD-ATFB-FK506, which is stored at 4°C in the dark.
[0016] Further, the preparation steps of the CD-ATFB-FK506 are as follows:
[0017] CD-ATFB and FK506 were uniformly mixed in a mass ratio of 1:1, dried at 60°C until the solvent was completely evaporated, and irradiated with ultraviolet light of a wavelength of 254 nm. After illumination, the product was dissolved in methanol to obtain CD-ATFB-FK506, which was stored at 4°C in the dark.
[0018] Furthermore, the position of the light source for the ultraviolet light irradiation is 2 cm away from the reactants.
[0019] Furthermore, the illumination time is more than 15 minutes.
[0020] Furthermore, the light source of the ultraviolet light comes from a handheld ultraviolet lamp.
[0021] In some embodiments, the preparation of CD-ATFB-FK506 is as follows: 5 mg of tetrafluoroazide photocrosslinked small molecule (CD-ATFB) and FK506 are mixed evenly at a mass ratio (1:1), transferred to a small glass dish, and placed in a 60°C oven to dry for 1 hour until the solvent is completely evaporated. A handheld ultraviolet lamp (wavelength = 254 nm) is used to illuminate at a distance of 2 cm from the bottom of the glass dish. After 15 minutes of illumination, the small molecule in the glass dish is transferred to a centrifuge tube with 2 mL of methanol and stored at 4°C in the dark.
[0022] Further, the synthesis method steps of the CD-ATFB are as follows:
[0023] Weigh Boc-CD-ATFB and dissolve it in dichloromethane. Add trifluoroacetic acid to react. Purify the crude product after the reaction by column. After spin drying, obtain slightly yellow sticky solid CD-ATFB.
[0024] Furthermore, the reagents used in the column purification are methanol:ethyl acetate, and the purification process is to purify methanol:ethyl acetate in a ratio of 1:16 and 1:8 in sequence.
[0025] Furthermore, the ratio of Boc-CD-ATFB, dichloromethane and trifluoroacetic acid is 0.213 mmol: 3 mL: 0.6 mL.
[0026] Furthermore, the reaction time is 3h.
[0027] In some embodiments, in order to remove the Boc protecting group, Boc-CD-ATFB (100 mg, 0.213 mmol) was weighed and dissolved in 3 mL of dichloromethane, and 600 μL of trifluoroacetic acid was added to react for 3 h. The crude product after the reaction was purified by column (methanol: ethyl acetate = 1:16 → 1:8), and a slightly yellow sticky solid CD-ATFB was obtained after spin drying.
[0028] Further, the synthesis method of Boc-CD-ATFB is as follows:
[0029] Weigh ATFB, EDC, and HOBT and dissolve them in dichloromethane for pre-activation. Then add Boc-CD diluted with dichloromethane dropwise for reaction. After the reaction is completed, wash three times with saturated NaCl solution, dry, filter, and purify the crude product by column. The product after spin drying is a white solid powder Boc-CD-ATFB.
[0030] Furthermore, the reagents used in the column purification are ethyl acetate:petroleum ether, and the purification process is to purify ethyl acetate:petroleum ether in a ratio of 1:8 and 1:4 in sequence.
[0031] Furthermore, the ratio of ATFB, EDC, HOBT and Boc-CD is 0.425 mmol: 1.276 mmol: 0.425 mmol: 0.85 mmol.
[0032] Furthermore, the volume ratio of the dichloromethane used to dissolve ATFB, EDC, and HOBT to the dichloromethane used to dilute Boc-CD was 12:3.
[0033] Furthermore, the reaction time is 12 hours.
[0034] Furthermore, the pre-activation time is 2 hours.
[0035] Furthermore, the drying is performed using anhydrous Na2SO4.
[0036] In some embodiments, the synthesis method of Boc-CD-ATFB is as follows: ATFB (100 mg, 0.425 mmol), EDC (244 mg, 1.276 mmol), and HOBT (57.43 mg, 0.425 mmol) are weighed and dissolved in 12 mL of dichloromethane and pre-activated for 2 h. Then, a mixed solution of Boc-CD (214.5 mg, 0.85 mmol) diluted with 3 mL of dichloromethane is added dropwise and reacted for 12 h. After the reaction is completed, it is washed three times with a saturated NaCl solution, dried with a little anhydrous Na2SO4, and the crude product obtained after filtration is purified by column (ethyl acetate: petroleum ether = 1: 8 → 1: 4), and the product after spin drying is a white solid powder Boc-CD-ATFB.
[0037] Further, the synthesis method of the Boc-CD is as follows:
[0038] Dissolve CD in methanol solution, add triethylamine, stir, slowly drop Boc anhydride diluted with methanol, stir to react, after the reaction is completed, spin dry the solvent, add 1M NaH2PO4 solution, extract the mixed solution 3 times, take the lower aqueous phase, adjust the pH value with 1M NaOH solution, extract 3 times with ethyl acetate, wash 3 times with saturated NaCl solution, collect the organic phase, dry it, filter the solution and spin dry to obtain a slightly yellow oily product Boc-CD.
[0039] Furthermore, the mixed solution 1 is a mixture of ethyl acetate and n-hexane, and the mixing ratio of ethyl acetate:n-hexane is 2:1.
[0040] Furthermore, the molar ratio of the CD to the Boc anhydride is 1:1.
[0041] Furthermore, the volume ratio of the methanol solution for dissolving CD to the methanol solution for diluting Boc anhydride was 9:1.
[0042] Furthermore, the stirring is magnetic stirring.
[0043] Furthermore, the ratio of CD to triethylamine is 4.44 mmol:2.446 mL.
[0044] Furthermore, the stirring reaction time is 12 hours.
[0045] Furthermore, the pH value is 9.
[0046] Furthermore, the drying is performed using anhydrous Na2SO4.
[0047] In some embodiments, the synthesis method of Boc-CD is as follows: CD (1g, 4.44mmol) is weighed, dissolved in 45mL methanol solution, 2.466mL triethylamine is added, and magnetic stirring is performed for 15min. After stirring, 5mL methanol-diluted Boc anhydride solution (1.022mL, 4.44mmol) is slowly added dropwise, and magnetic stirring is performed overnight. After the reaction is completed, the solvent is spin-dried, and an appropriate amount of 1MNaH2PO4 solution is added and transferred to a separatory funnel, and extracted 3 times with a mixed solution of ethyl acetate: n-hexane (2:1) to remove the double Boc-protected cystamine product impurities. Take the lower aqueous phase, adjust the pH to about 9 with 1MNaOH solution, continue to extract with ethyl acetate 3 times, wash with saturated NaCl solution 3 times, collect the organic phase, add a little anhydrous Na2SO4 to dry, and filter the solution to obtain a slightly yellow oily product Boc-CD.
[0048] In some embodiments, a modified small molecule photocrosslinking method is used to excite the azide group on 4-azido-2,3,5,6-tetrafluorobenzoic acid (ATFB) under the irradiation of ultraviolet light to generate "nitrene", which is successfully photocrosslinked with tacrolimus (FK506) to form a small molecule photocrosslinking complex (CD-ATFB-FK506).
[0049] Further, the preparation steps of the Fe3O4@C are as follows:
[0050] The Fe3O4 magnetic nanoparticles were mixed with 0.1M HNO3 solution, ultrasonically treated, washed with deionized water until neutral, added with 0.5M glucose solution containing 10% v / v acrylic acid, and reacted at 200°C after ultrasonic treatment. After the reaction was completed, the mixture was naturally cooled to room temperature, the product was collected by magnetic separation, and washed alternately with deionized water and methanol.
[0051] Furthermore, the ratio of the Fe3O4 magnetic nanoparticles to the HNO3 solution is 200 mg:80 mL.
[0052] Furthermore, the ratio of the Fe3O4 magnetic nanoparticles to the glucose solution is 200 mg:70 mL.
[0053] Furthermore, the reaction time at 200° C. is 6 hours.
[0054] Furthermore, the Fe3O4@C is stored at 4°C.
[0055] Furthermore, the reaction is carried out in a reactor at 200°C.
[0056] In some embodiments, in order to improve the biocompatibility and physical stability of Fe3O4, a carbon layer is modified on the outer layer of Fe3O4 through a second hydrothermal synthesis to prepare Fe3O4@C magnetic carbon nanoparticles with a core-shell structure, introduce carboxylation sites, and improve the hydrophilicity of the material.
[0057] Further, the preparation method of the Fe3O4 magnetic nanoparticles comprises the following steps:
[0058] Weigh FeCl3·6H2O, dissolve it in ethylene glycol, stir, and obtain an orange-yellow solution after it is fully dissolved, add anhydrous sodium acetate, continue stirring, continue to react at 200°C, and after the reaction is completed, naturally cool to room temperature, collect the product by magnetic separation, and wash it with deionized water and anhydrous ethanol several times to obtain Fe3O4 magnetic nanoparticles.
[0059] Furthermore, the reaction is carried out in a reactor at 200°C.
[0060] Furthermore, the ratio of FeCl3·6H2O to ethylene glycol is 1 g:40 mL.
[0061] Furthermore, the stirring is carried out by magnetic stirring.
[0062] Furthermore, the mass ratio of the FeCl3·6H2O to anhydrous sodium acetate is 1:1.92.
[0063] Furthermore, the Fe3O4 magnetic nanoparticles are stored at 4°C.
[0064] In some embodiments, Fe3O4 magnetic nanoparticles with uniform particle size and excellent morphology are synthesized by a solvothermal method.
[0065] The present invention provides a nitrene-type photo-crosslinked magnetic carbon bioprobe. The nitrene-type photo-crosslinked magnetic carbon bioprobe is prepared by the above-mentioned preparation method. The nitrene-type photo-crosslinked magnetic carbon bioprobe is also called Fe3O4@C-CD-ATFB-FK506.
[0066] The present invention provides a method for drug targeting identification, the method comprising the following steps:
[0067] The aforementioned nitrene-type photo-cross-linked magnetic carbon bioprobe was incubated with the cell lysate, and non-specific binding proteins were removed by washing with a buffer solution. The supernatant was collected after DTT treatment and analyzed. The buffer solution components were 0.25 M sucrose, 0.3 mM ethylenediaminetetraacetic acid, 25 mM Tris-HCl, and the pH of the buffer solution was 7.5.
[0068] Furthermore, the analysis of the supernatant includes SDS-PAGE analysis and / or MS / MS identification.
[0069] Furthermore, the cells include brain tissue / cells, nerve tissue / cells, vascular tissue / cells, and tumor tissue / cells.
[0070] Furthermore, the aforementioned nitrene-type photo-crosslinked magnetic carbon bioprobe specifically binds to peptidyl prolyl cis-trans isomerase.
[0071] Furthermore, the peptidyl prolyl cis-trans isomerase is FKBP12.
[0072] Furthermore, after the supernatant is collected after the DTT treatment, a concentration step is performed, and the concentration ratio is 40 microliters per milliliter of solution.
[0073] Furthermore, the DTT treatment specifically uses a 20 mM DTT solution, which is obtained by dissolving DTT in a PB buffer solution.
[0074] Furthermore, the ratio of DTT to the co-incubated product is 1 mL:15 mg.
[0075] Furthermore, the DTT treatment time is 3 hours.
[0076] Furthermore, after the concentration, SDS loading buffer was added, boiled, and MS / MS identification was performed.
[0077] Furthermore, the boiling time is 5 minutes.
[0078] Furthermore, the volume ratio between the concentrated solution and the loading buffer solution is 4:1.
[0079] Furthermore, after the supernatant is collected after the DTT treatment, ultrapure water and SDS loading buffer are added, boiled, and subjected to SDS-PAGE analysis.
[0080] Furthermore, the boiling time is 5 minutes.
[0081] Furthermore, after the supernatant was collected after the DTT treatment, ultrapure water and SDS loading buffer were added in a ratio of 40 μL:10 μL.
[0082] Furthermore, the co-incubation time is 2 hours.
[0083] In some embodiments, tacrolimus (FK506) with a clear drug-protein mechanism of action and its target protein peptidyl prolyl cis-trans isomerase (FKBP12) are used as a model system for affinity purification, and a non-drug group Fe3O4@C-CD-ATFB is added as a blank control to verify the ability of the above probe to capture and release the target protein. First, the two different materials are applied to complex mouse brain biological samples, and after extensive washing to remove most of the non-specific binding proteins, they are treated with dithiothreitol (DTT) respectively, and the eluted supernatant after DTT treatment is subjected to SDS-PAGE and MS / MS to obtain data and analyze them.
[0084] The present invention provides the above-mentioned preparation method or the application of the above-mentioned nitrene-type photo-cross-linked magnetic carbon biological probe in products for small molecule drug target detection, probe capture, and target protein release.
[0085] Furthermore, the target protein is peptidyl prolyl cis-trans isomerase.
[0086] Furthermore, the peptidyl prolyl cis-trans isomerase is FKBP12.
[0087] The present invention provides the application of the above-mentioned method for drug target identification in the preparation of an automated small molecule drug target detection device.
[0088] The term "CD" used in the present invention is also known as cystamine dihydrochloride, which introduces a cleavable disulfide bond into the system to reduce nonspecific adsorption caused by the matrix.
[0089] The term "FK506" used in the present invention is also known as tacrolimus, which is an immunosuppressive drug and a macrolide lactone.
[0090] The term "FKBP12" used in the present invention is a peptidyl prolyl cis-trans isomerase (PPIase). FKBP12 accelerates protein folding by catalyzing the isomerization of the proline imide peptide bond in oligopeptides. The multiple functions of FKBP12 highlight its regulatory role in various cellular processes.
[0091] The term "Boc" used in the present invention is also known as di-tert-butyl dicarbonate, Boc anhydride, and is a new type of amino protecting agent.
[0092] The term "ATFB" used in the present invention is also known as 4-azido-2,3,5,6-tetrafluorobenzoic acid, which is a click chemistry reagent containing an azide group and can be used as a multifunctional photoaffinity labeling agent for detecting biological receptors.
[0093] The term "EDC" as used in the present invention is also known as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, which is a zero-length crosslinker used to couple carboxyl groups to primary amines. This crosslinker has been used in a variety of applications, such as forming amide bonds in peptide synthesis, linking haptens to carrier proteins to form immunogens, labeling nucleic acids via 5' phosphate groups, and constructing amine-reactive NHS esters of biomolecules. EDC reacts with carboxyl groups to form amine-reactive O-acylisourea intermediates.
[0094] The term "HOBT" used in the present invention is also known as 1-hydroxybenzotriazole, which is a derivative of benzotriazole in which the 1H-N is substituted by a hydroxyl group. It is often used as a racemization inhibitor in peptide synthesis.
[0095] The term "DTT" used in the present invention is also known as dithiothreitol, which is a small molecule organic reducing agent.
[0096] Advantages and beneficial effects of the present invention:
[0097] The present invention provides a method for preparing a nitrene-type photo-crosslinked magnetic carbon bioprobe (Fe3O4@C-CD-ATFB-FK506). First, a tetrafluoroazide photo-crosslinked small molecule CD-ATFB containing a cleavable disulfide bond is synthesized, then it is mixed with a drug molecule FK506 and then irradiated with ultraviolet light to form a CD-ATFB-FK506 photo-crosslinked complex, and finally CD-ATFB-FK506 is fixed on the Fe3O4@C surface through amide condensation.
[0098] The modified small molecule photocrosslinking method provided by the present invention has the following advantages: (1) It has a certain degree of versatility, greatly improving the synthesis efficiency of the probe, and there is no need to conduct structure activity relationship (SAR) research on the probe. A variety of active molecules can be fixed without chemical modification, providing a fixation idea for biologically active small molecules that do not have the conditions for derivatization; (2) This method is fast and easy to use because chemical fixation is achieved by ultraviolet irradiation; (3) This will also allow small molecules to bind to all potential proteins because the fixed small molecule structure may be diverse.
[0099] The method provided by the present invention uses tetrafluoroazide-type photocrosslinking small molecules with high reaction efficiency, fast kinetics, excellent storage stability and low price as the hub for connecting active molecules. The modified small molecule photocrosslinking method adopted is simple to operate, has certain versatility, and greatly improves the synthesis efficiency of the probe. A disulfide bond is introduced into the probe and a non-drug group is set as a control experiment to eliminate nonspecific interference introduced by the matrix. The method has a simple synthesis process, low cost and is green and environmentally friendly; the active small molecule drug fixation method proposed by the present invention provides a certain idea for exploring unknown small molecule drug targets. BRIEF DESCRIPTION OF THE DRAWINGS
[0100] Figure 1 This is the synthetic route of CD-ATFB;
[0101] Figure 2 It is a schematic diagram of the synthesis route involved in the present invention;
[0102] Figure 3 are transmission electron microscopy images: (a) Fe3O4, (b) Fe3O4@C;
[0103] Figure 4 It is the hysteresis curve diagram of Fe3O4 and Fe3O4@C;
[0104] Figure 5 Fourier transform infrared spectra, (a) Fe3O4, (b) Fe3O4@C;
[0105] Figure 6 Mass spectrometry chromatograms, (a) the product after photocrosslinking of CD-ATFB and FK506, (b) the supernatant after DTT treatment of Fe3O4@C-CD-ATFB-FK506, (c) the supernatant after DTT treatment of Fe3O4@C-CD-ATFB;
[0106] Figure 7 is an application flow chart of the present invention;
[0107] Figure 8This is a visualization analysis of FKBP12 release in rat brain lysate by SDS-PAGE electrophoresis, (1): Marker; (2): rat brain lysate; (4) and (6) are the supernatants of Fe3O4@C-CD-ATFB-FK506 and Fe3O4@C-CD-ATFB after incubation with rat brain lysate and then treated with DTT; (3) and (5) are the residual proteins of Fe3O4@C-CD-ATFB-FK506 and Fe3O4@C-CD-ATFB after treatment with DTT. DETAILED DESCRIPTION
[0108] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes based on the technical solution and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
[0109] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0110] Example 1. Preparation of Nitrile-type photo-crosslinked magnetic carbon bioprobe (Fe3O4@C-CD-ATFB-FK506)
[0111] 1. Preparation steps
[0112] Preparation of Fe3O4@C magnetic carbon nanoparticles
[0113] 1.1 Preparation of Fe3O4@C magnetic carbon nanoparticles
[0114] (1) Preparation of Fe3O4 magnetic nanoparticles
[0115] Weigh 1g of FeCl3·6H2O and dissolve it in a conical flask containing 40mL of ethylene glycol. Stir magnetically for 30min to obtain an orange-yellow solution after full dissolution. Next, weigh 1.92g of oven-dried anhydrous sodium acetate and add it to the conical flask, and continue stirring for 1h. After stirring, transfer the mixed solution to a 50mL reactor, put it in an oven, and continue to react at 200℃ for 10h. After the reaction is completed, wait for the reactor to cool naturally to room temperature, collect the product by magnetic separation, wash it several times with deionized water and anhydrous ethanol, and store it at 4℃.
[0116] (2) Preparation of Fe3O4@C magnetic carbon nanoparticles
[0117] Take 200mgFe3O4 magnetic nanoparticles, transfer them to a three-necked bottle with 80mL0.1M HNO3 solution, ultrasonically treat for 20min, and wash the material with deionized water several times until neutral. Then, prepare 70mL0.5M glucose solution (containing 10% v / v acrylic acid), transfer the above treated material to the three-necked bottle, and ultrasonically treat for 40min. After the ultrasonic treatment, transfer the liquid in the three-necked bottle to the reactor and react in an oven at 200℃ for 6h. After the reaction, wait for the reactor to cool naturally to room temperature, collect the product by magnetic separation, wash it several times with deionized water and methanol alternately, and store it at 4℃.
[0118] 1.2 Preparation of tetrafluoroazide photocrosslinking small molecule CD-ATFB containing cleavable disulfide bonds
[0119] The synthetic route of CD-ATFB is as follows Figure 1 shown.
[0120] (1) Synthesis of Boc-CD small molecules
[0121] Weigh CD (1 g, 4.44 mmol), dissolve in 45 mL of methanol solution, add 2.466 mL of triethylamine, and stir magnetically for 15 min. After stirring, slowly add 5 mL of methanol-diluted Boc anhydride solution (1.022 mL, 4.44 mmol) dropwise, and stir magnetically for 12 h.
[0122] After the reaction, the solvent was dried by spin drying, and an appropriate amount of 1M NaH2PO4 solution was added and transferred to a separatory funnel, and extracted three times with a mixed solution of ethyl acetate: n-hexane (2:1) to remove the impurities of the double Boc-protected cystamine product. The lower aqueous phase was taken, and the pH was adjusted to about 9 with a 1M NaOH solution, and ethyl acetate was continuously extracted three times. After washing with a saturated NaCl solution three times, the organic phase was collected, a small amount of anhydrous Na2SO4 was added, and dried. The solution obtained after filtration was spin dried to obtain a slightly yellow oily product Boc-CD.
[0123] Yield: 40.2%
[0124] 1 H NMR (400 MHz, CHLOROFORM-d) δ 4.95 (s, 1H), 3.45 (q, J = 5.6, 5.1 Hz, 2H), 3.01 (t, J = 6.0 Hz, 2H), 2.84-2.77 (m, 2H), 2.75 (d, J = 6.2 Hz, 2H), 1.43 (s, 9H).
[0125] (2) Synthesis of Boc-CD-ATFB
[0126] ATFB (100 mg, 0.425 mmol), EDC (244 mg, 1.276 mmol), and HOBT (57.43 mg, 0.425 mmol) were weighed and dissolved in 12 mL of dichloromethane and pre-activated for 2 h. Then, a mixed solution of Boc-CD (214.5 mg, 0.85 mmol) diluted with 3 mL of dichloromethane was added dropwise and reacted for 12 h.
[0127] After the reaction, the mixture was washed three times with saturated NaCl solution, dried by adding a little anhydrous Na2SO4, filtered, and the obtained crude product was purified by column chromatography (ethyl acetate: petroleum ether = 1:8→1:4). The product was spin-dried to obtain a white solid powder Boc-CD-ATFB.
[0128] Yield: 65%
[0129] 1 H NMR (400MHz, chloroform-d) δ7.48 (s, 1H), 4.93 (s, 1H), 3.76 (q, J = 5.9Hz, 2H), 3.43 ( q,J=6.9Hz,2H),2.97(t,J=5.9Hz,2H),2.75(t,J=7.2Hz,2H),1.33(s,9H).
[0130] (3) Synthesis of CD-ATFB
[0131] In order to remove the Boc protecting group, Boc-CD-ATFB (100 mg, 0.213 mmol) was weighed and dissolved in 3 mL of dichloromethane, and 600 μL of trifluoroacetic acid was added and reacted for 3 h.
[0132] The crude product after the reaction was purified by column (methanol:ethyl acetate=1:16→1:8), and was spin-dried to obtain a slightly yellow sticky solid CD-ATFB.
[0133] Yield: 95%
[0134] 1 H NMR (400 MHz, dimethyl sulfoxide-d6) δ 9.22 (d, J = 19.5 Hz, 1H), 3.56 (q, J = 5.9 Hz, 2H), 3.10 (t, J = 7.1 Hz, 2H), 2.98-2.93 (m, 2H), 2.90 (t, J = 6.6 Hz, 2H).
[0135] 1.3 Preparation of small molecule photocrosslinking complex CD-ATFB-FK506
[0136] 5 mg of tetrafluoroazide photocrosslinked small molecule (CD-ATFB) and FK506 were mixed evenly at a mass ratio of (1:1), then transferred to a small glass dish and placed in a 60°C oven for drying for 1 hour until the solvent was completely evaporated. A handheld UV lamp (wavelength = 254 nm) was used to illuminate the small molecule at a distance of 2 cm from the bottom of the glass dish. After 15 minutes of illumination, the small molecule in the glass dish was transferred to a centrifuge tube with 2 mL of methanol and stored at 4°C in the dark.
[0137] 1.4 Preparation of Fe3O4@C-CD-ATFB-FK506
[0138] Take 100mg Fe3O4@C nanoparticles, wash them three times with methanol, prepare 50mg photo-crosslinked composite CD-ATFB-FK506 and add it. Then add 400mg EDC and 300μL triethylamine and react for 12h. After the reaction, the material is washed several times with methanol and quantified in deionized water to obtain Fe3O4@C-CD-ATFB-FK506, which is stored at 4℃ in the dark.
[0139] The preparation route of nitrene-type photocrosslinked magnetic carbon bioprobe (Fe3O4@C-CD-ATFB-FK506) is as follows: Figure 2 shown.
[0140] 2. Preparation effect verification
[0141] like Figure 3 As shown in Figure A, the unmodified Fe3O4 nanoparticles are regular spherical with an average particle size of 376nm. In Figure B, the modified Fe3O4@C nanoparticles are coated with a carbon layer after hydrothermal carbonization of glucose and have a core-shell structure with an average particle size of 436nm and a carbon layer thickness of about 30nm. The above results show that the Fe3O4@C nanoparticles are composed of an internal magnetic core and an external carbon layer, forming a uniform core-shell structure, showing good morphological characteristics, and further improving the stability of the material.
[0142] like Figure 4 As shown in the figure, the magnetic intensity values of Fe3O4 and Fe3O4@C nanoparticles are 47.8emu / g and 38.9emu / g, respectively. Although the magnetic intensity value of the modified Fe3O4@C nanoparticles has decreased, they still maintain superparamagnetism. In addition, the magnetic responsiveness test shows that under the action of an external magnetic field, Fe3O4@C nanoparticles can quickly move toward the magnetic field to achieve the effect of rapid magnetic separation, with good magnetic responsiveness, which greatly improves the efficiency of subsequent protein affinity purification experiments.
[0143] like Figure 5As shown in Figure 2, curves a and b are the infrared absorption spectra of Fe3O4 and Fe3O4@C nanoparticles, respectively. In the infrared spectrum of Fe3O4 (curve a), a peak at 585 cm -1 The vibration peak of Fe-O at 1734cm is a typical characteristic peak of Fe3O4. After a thin layer of carbon is coated on the surface of Fe3O4 (curve b), a peak at 1734cm -1 The signal at 1635 cm-1 is attributed to C=O. -1 The C=C signals at the bottom of the graphene are due to the cycloaddition reaction of glucose during the hydrothermal carbonization process, which causes the carboxyl groups of acrylic acid to be grafted onto the material. These results indicate that the carboxyl groups on the surface of the material have been successfully modified, providing carboxylation sites for the subsequent derivatization of the material.
[0144] like Figure 6 As shown in Figure a, a chromatographic peak consistent with the molecular weight of the expected photo-crosslinked molecule (CD-ATFB-FK506) of 1146.3743 appears at 5.61 min. In Figure b, a chromatographic peak consistent with the molecular weight of the expected derivative of 1071.2415 appears at 4.69 min and 4.91 min in the Fe3O4@C-CD-ATFB-FK506 treated group, but not in the Fe3O4@C-CD-ATFB untreated group (c), proving that FK506 has been successfully fixed on Fe3O4@C, that is, Fe3O4@C-CD-ATFB-FK506 was successfully prepared.
[0145] Example 2: Affinity purification application of nitrene-type photo-crosslinked magnetic carbon bioprobe in mouse brain lysate
[0146] Fe3O4@C-CD-ATFB-FK506 and Fe3O4@C-CD-ATFB were used for affinity purification of the target. The experimental process is as follows: Figure 7 shown.
[0147] 1. Experimental methods
[0148] Preparation of rat brain lysate: Take fresh rat brain tissue, cut the tissue into pieces, and wash it three times with pre-cooled PBS buffer (PH = 7.4). Put an appropriate amount of tissue (65 mg) into an EP tube, add RIPA lysis buffer (1.3 mL) containing 1% PMSF, and use an ultrasonic cell disruptor to fully lyse the tissue to extract protein. Ultrasonicate for 10 seconds, stop for 2 seconds, and continue for 8 minutes. All operations are performed on ice. After complete lysis, centrifuge at 12000rpm to remove the supernatant, measure the total protein concentration using the bicinchoninic acid (BCA) method, and store it in a -80°C refrigerator.
[0149] Fe3O4@C-CD-ATFB-FK506 and Fe3O4@C-CD-ATFB were incubated with the above-mentioned mouse brain protein biological samples. After extensive washing with buffers of different concentrations, 1 mL of 20 mM DTT solution prepared with PB buffer (PH = 7.4) was taken as a bond breaking solution and added to the above-mentioned materials respectively, and shaken for 3 hours. After the treatment, the supernatant was removed by centrifugation, and the eluate was concentrated to ~40 μL using a 10 kDa ultrafiltration centrifuge tube (Amicon-Ultra-15), and 10 μL of SDS loading buffer was added and boiled at 100 ° C for 5 min, and the supernatant was centrifuged for use. The remaining materials were added with 40 μL of ultrapure water and 10 μL of SDS loading buffer and boiled at 100 ° C for 5 min, and the supernatant was centrifuged again for use. All denatured supernatant samples were analyzed by 15% SDS-PAGE and visualized by silver staining, and the amount of eluate loaded was kept consistent (10 μL).
[0150] like Figure 8 As shown, Lane 1 is the marker band, and Lane 2 is the mother liquor band of rat brain lysate (Ratbrain). Lane 4 and Lane 6 are the bond-breaking supernatants obtained after Fe3O4@C-CD-ATFB-FK506 and Fe3O4@C-CD-ATFB probes were treated with DTT. The red arrow indicates a protein with a large difference. It is speculated that the protein here is FKBP12 (12KDa), and its band molecular weight is similar. The corresponding eluates in Lane 4 and Lane 6 were subjected to protein spectrum analysis and identification, and the test results are shown in Table 1.
[0151] Table 1. FKBP12 identified after enzyme digestion and MS / MS analysis of the eluted solution
[0152]
[0153] As shown in Table 1, FKBP12 was not identified in the Fe3O4@C-CD-ATFB without drug treatment, and the corresponding target protein FKBP12 was successfully identified in the Fe3O4@C-CD-ATFB-FK506 with drug treatment. A total of 4 peptides were identified, all of which were unique peptides, and the peptide sequence coverage rate was 43.5%. It can be concluded that the magnetic carbon bioprobe synthesized in the present invention can effectively capture and specifically release the bound target protein, and is expected to be used for the identification and detection of unknown drug targets.
[0154] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. A method for preparing a nitrene-type photocrosslinked magnetic carbon bioprobe, the preparation method comprising the following steps: CD-ATFB-FK506 was introduced onto the Fe3O4@C surface by amide condensation to obtain the nitrene-type photo-cross-linked magnetic carbon bioprobe Fe3O4@C-CD-ATFB-FK506.
2. The preparation method according to claim 1, comprising the following steps: The Fe3O4@C nanoparticles were washed with methanol three times, added with the photo-crosslinked composite CD-ATFB-FK506, and then with EDC and triethylamine for reaction. After the reaction was completed, the nanoparticles were washed to obtain Fe3O4@C-CD-ATFB-FK506. Preferably, the washing is methanol washing; Preferably, the washing is followed by quantification in water; Preferably, the ratio of the Fe3O4@C nanoparticles, the photocrosslinked composite CD-ATFB-FK506, EDC, and triethylamine is 100 mg: 50 mg: 400 mg: 0.3 mL; Preferably, the Fe3O4@C-CD-ATFB-FK506 is stored at 4°C in the dark; Preferably, the reaction time is 12 h.
3. The preparation method according to claim 1, wherein the preparation steps of CD-ATFB-FK506 are as follows: CD-ATFB and FK506 were mixed evenly at a mass ratio of 1:1, dried at 60°C until the solvent was completely volatilized, and irradiated with ultraviolet light of a wavelength of 254 nm. After irradiation, the product was dissolved in methanol to obtain CD-ATFB-FK506, which was stored at 4°C in the dark; Preferably, the ultraviolet light source is 2 cm away from the reactant; Preferably, the illumination time is more than 15 minutes; Preferably, the light source of the ultraviolet light comes from a handheld ultraviolet lamp; Preferably, the synthesis method of CD-ATFB comprises the following steps: Weigh Boc-CD-ATFB and dissolve it in dichloromethane, add trifluoroacetic acid, react, purify the crude product after the reaction by column, and spin dry to obtain slightly yellow sticky solid CD-ATFB; Preferably, the reagent used in the column purification is methanol:ethyl acetate, and the purification process is methanol:ethyl acetate in a ratio of 1:16 and 1:8 in sequence; Preferably, the ratio of Boc-CD-ATFB, dichloromethane, and trifluoroacetic acid is 0.213 mmol: 3 mL: 0.6 mL; Preferably, the reaction time is 3h; Preferably, the synthesis method of Boc-CD-ATFB comprises the following steps: Weigh ATFB, EDC, and HOBT and dissolve them in dichloromethane for pre-activation. Then, add Boc-CD diluted with dichloromethane dropwise for reaction. After the reaction is completed, wash three times with a saturated NaCl solution, dry, filter, and purify the crude product by column. After spin drying, the product is a white solid powder Boc-CD-ATFB. Preferably, the reagent used in the column purification is ethyl acetate: petroleum ether, and the purification process is to purify ethyl acetate: petroleum ether in a ratio of 1:8 and 1:4 in sequence; Preferably, the ratio of ATFB, EDC, HOBT, and Boc-CD is 0.425mmol:1.276mmol:0.425mmol:0.85mmol; Preferably, the volume ratio of dichloromethane used to dissolve ATFB, EDC, and HOBT to dichloromethane used to dilute Boc-CD is 12:3; Preferably, the reaction time is 12h; Preferably, the pre-activation time is 2h; Preferably, the drying is carried out using anhydrous Na2SO4; Preferably, the synthesis method of Boc-CD comprises the following steps: CD was dissolved in methanol solution, triethylamine was added, stirred, and Boc anhydride diluted with methanol was slowly added dropwise, stirred and reacted. After the reaction was completed, the solvent was dried by spin drying, 1M NaH2PO4 solution was added, and the mixed solution was extracted 3 times. The lower aqueous phase was taken, the pH value was adjusted with 1M NaOH solution, extracted 3 times with ethyl acetate, washed 3 times with saturated NaCl solution, and the organic phase was collected and dried. The solution obtained after filtration was spin dried to obtain a slightly yellow oily product Boc-CD; Preferably, the mixed solution 1 is a mixture of ethyl acetate and n-hexane, and the mixing ratio of ethyl acetate:n-hexane is 2:1; Preferably, the ratio of the amount of CD to Boc anhydride is 1:1; Preferably, the volume ratio of the methanol solution for dissolving CD to the methanol solution for diluting Boc anhydride is 9:1; Preferably, the stirring is magnetic stirring; Preferably, the ratio of CD to triethylamine is 4.44mmol:2.446mL; Preferably, the stirring reaction time is 12h; Preferably, the pH value is 9; Preferably, the drying is performed using anhydrous Na2SO4.
4. The preparation method according to claim 1, wherein the preparation steps of Fe3O4@C are as follows: The Fe3O4 magnetic nanoparticles were mixed with 0.1M HNO3 solution, ultrasonically treated, washed with deionized water until neutral, added with 0.5M glucose solution containing 10% v / v acrylic acid, ultrasonically treated, reacted at 200°C, and after the reaction was completed, cooled naturally to room temperature, the product was collected by magnetic separation, and washed alternately with deionized water and methanol; Preferably, the ratio of the Fe3O4 magnetic nanoparticles to the HNO3 solution is 200 mg: 80 mL; Preferably, the ratio of the Fe3O4 magnetic nanoparticles to the glucose solution is 200 mg:70 mL; Preferably, the reaction time at 200° C. is 6 h; Preferably, the Fe3O4@C is stored at 4°C; Preferably, the reaction is carried out in a reactor at 200°C; Preferably, the preparation method of the Fe3O4 magnetic nanoparticles comprises the following steps: Weigh FeCl3·6H2O, dissolve it in ethylene glycol, stir, and obtain an orange-yellow solution after it is fully dissolved, add anhydrous sodium acetate, continue stirring, and continue to react at 200°C after the stirring is completed. After the reaction is completed, naturally cool to room temperature, collect the product by magnetic separation, and wash it with deionized water and anhydrous ethanol several times to obtain Fe3O4 magnetic nanoparticles; Preferably, the reaction is carried out in a reactor at 200°C; Preferably, the ratio of FeCl3·6H2O to ethylene glycol is 1 g:40 mL; Preferably, the stirring is carried out by magnetic stirring; Preferably, the mass ratio of FeCl3·6H2O to anhydrous sodium acetate is 1:1.92; Preferably, the Fe3O4 magnetic nanoparticles are stored at 4°C.
5. A nitrene-type photo-crosslinked magnetic carbon bioprobe, which is prepared by the preparation method described in any one of claims 1 to 4. The nitrene-type photo-crosslinked magnetic carbon bioprobe is also called Fe3O4@C-CD-ATFB-FK506.
6. A method for drug targeting identification, the method comprising the following steps: The nitrene-type photo-crosslinked magnetic carbon bioprobe described in claim 5 is co-incubated with a cell lysate, non-specific binding proteins are removed by washing with a buffer solution, the supernatant is collected after DTT treatment, and the supernatant is analyzed, the buffer solution components are 0.25M sucrose, 0.3mM ethylenediaminetetraacetic acid, 25mM Tris-HCl, and the pH of the buffer solution is 7.
5.
7. The method of claim 6, wherein the analysis of the supernatant comprises SDS-PAGE analysis and / or MS / MS identification; Preferably, the cells include brain tissue / cells, neural tissue / cells, vascular tissue / cells, and tumor tissue / cells; Preferably, the nitrene-type photo-crosslinked magnetic carbon bioprobe described in claim 5 specifically binds to peptidyl prolyl cis-trans isomerase; Preferably, the peptidyl prolyl cis-trans isomerase is FKBP12.
8. The method of claim 6, wherein after collecting the supernatant after the DTT treatment, a concentration step is performed, and the concentration ratio is 40 μl per ml of solution; Preferably, the DTT treatment specifically uses a 20 mM DTT solution, wherein the DTT solution is obtained by dissolving DTT in a PB buffer; Preferably, the ratio of DTT to the co-incubated product is 1 mL: 15 mg; Preferably, the DTT treatment time is 3h; Preferably, after the concentration, SDS loading buffer is added, boiled, and MS / MS identification is performed; Preferably, the boiling time is 5 min; Preferably, the volume ratio between the concentrated solution and the loading buffer is 4:1; Preferably, after collecting the supernatant after the DTT treatment, ultrapure water and SDS loading buffer are added, boiled, and subjected to SDS-PAGE analysis; Preferably, the boiling time is 5 min; Preferably, after collecting the supernatant after the DTT treatment, ultrapure water and SDS loading buffer are added in a ratio of 40 μL:10 μL; Preferably, the co-incubation time is 2 h.
9. Use of the preparation method according to any one of claims 1 to 4, or the nitrene-type photo-crosslinked magnetic carbon bioprobe according to claim 5 in products for small molecule drug target detection, probe capture, and target protein release; Preferably, the target protein is peptidyl prolyl cis-trans isomerase; Preferably, the peptidyl prolyl cis-trans isomerase is FKBP12.
10. Use of the method for drug targeting identification according to any one of claims 6 to 8 in preparing an automated small molecule drug target detection device.
